Bayer picks up off-the-shelf CAR-T approach from Atara, spotlighting a Memorial Sloan Kettering breakthrough
Bayer’s brand new cell & gene therapy strategy now also features CAR-T.
In a new deal with Atara Biotherapeutics, the German pharma has reserved $610 million — $60 million of that upfront — to spend on two cell therapies directed at mesothelin. ATA3271, an off-the-shelf therapy, is the main focus but an autologous version of it is also part of the pact.
The goal? To go after high mesothelin-expressing solid tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.